Genentech's Lunsumio-based Regimen Meets Primary Goal In Phase III Study In Follicular Lymphoma
(RTTNews) - Genentech, affiliated to Swiss drug major Roche Holding AG (RHHBY, RO.SW, ROG.SW), on Thursday announced that its Lunsumio-based regimen significantly improved progression-free survival in Follicular Lymphoma or FL in phase III CELESTIMO study …